The recent studies evaluating CAR-T therapy have reported rapid evolution of existing CH, particularly TP53-mutated clones in patients with multiple myeloma, and expansion of CH and a shorter duration, compared with traditional chemotherapy, to sMNs in patients with LBCL (38–40). This evidence concerns the gene TP53 and plasma cell myeloma.